Home LiteratureArticle Details
PMID: 29489423 Published · ppublish English Journal Article Review

Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma.

Journal of dental research ·Vol. 97 ·No. 6 ·2018-00-00 ·Pages 622-626

Moskovitz JM, Ferris RL

Abstract

The immune system plays an important role in the evolution of malignancy and has become an important target for novel antineoplastic agents. This review article focuses on key features of tumor immunology, including the role of immunotherapy in general and as it pertains to head and neck squamous cell carcinoma. Side effects, resistance mechanisms, and therapeutic monitoring strategies pertaining to immunotherapy are discussed.

Keywords
T lymphocyte cancer biology checkpoint receptors clinical trials immune resistance neoadjuvant immunotherapy
MeSH Terms
Carcinoma, Squamous Cell/immunology,therapy Head and Neck Neoplasms/immunology,therapy Humans Immunotherapy/methods
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Moskovitz J M
1 Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.
Ferris R L
2 UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
References (46)
46 references, click to expand
  1. Cancer immunoediting: from immunosurveillance to tumor escape.
    Nat Immunol. 2002 Nov;3(11):991-8 PMID: 12407406
  2. Dynamics of cell surface molecules during T cell recognition.
    Annu Rev Biochem. 2003;72:717-42 PMID: 14527326
  3. Peptide-based vaccines for cancer immunotherapy.
    Expert Opin Biol Ther. 2004 Feb;4(2):181-98 PMID: 14998777
  4. Memory CD8 T-cell differentiation during viral infection.
    J Virol. 2004 Jun;78(11):5535-45 PMID: 15140950
  5. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2004 Jun 1;10(11):3755-62 PMID: 15173082
  6. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223).
    J Immunol. 2005 Jan 15;174(2):688-95 PMID: 15634887
  7. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.
    J Immunol. 2006 Mar 15;176(6):3402-9 PMID: 16517708
  8. Molecular signature of CD8+ T cell exhaustion during chronic viral infection.
    Immunity. 2007 Oct;27(4):670-84 PMID: 17950003
  9. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
    Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10 PMID: 18287062
  10. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.
    Nat Immunol. 2009 Jan;10(1):29-37 PMID: 19043418
  11. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells.
    J Immunol. 2009 Jun 1;182(11):6659-69 PMID: 19454660
  12. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
    J Exp Med. 2009 Aug 3;206(8):1717-25 PMID: 19581407
  13. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
    Clin Cancer Res. 2009 Dec 1;15(23):7412-20 PMID: 19934295
  14. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice.
    J Exp Med. 2011 Feb 14;208(2):395-407 PMID: 21300912
  15. Vstm3 is a member of the CD28 family and an important modulator of T-cell function.
    Eur J Immunol. 2011 Apr;41(4):902-15 PMID: 21416464
  16. IL-18 induces PD-1-dependent immunosuppression in cancer.
    Cancer Res. 2011 Aug 15;71(16):5393-9 PMID: 21724589
  17. The blockade of immune checkpoints in cancer immunotherapy.
    Nat Rev Cancer. 2012 Mar 22;12(4):252-64 PMID: 22437870
  18. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
    Sci Transl Med. 2012 Mar 28;4(127):127ra37 PMID: 22461641
  19. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    N Engl J Med. 2012 Jun 28;366(26):2443-54 PMID: 22658127
  20. Radiation, inflammation, and immune responses in cancer.
    Front Oncol. 2012 Jun 04;2:58 PMID: 22675673
  21. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
    J Exp Med. 2013 Aug 26;210(9):1695-710 PMID: 23897981
  22. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
    Oncoimmunology. 2014 Jan 1;3(1):e27614 PMID: 24701377
  23. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
    Clin Cancer Res. 2014 Oct 1;20(19):5064-74 PMID: 24714771
  24. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.
    Immunity. 2014 Apr 17;40(4):569-81 PMID: 24745333
  25. Opportunistic infections in patients treated with immunotherapy for cancer.
    J Immunother Cancer. 2014 Jun 18;2:19 PMID: 24991413
  26. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence.
    Clin Cancer Res. 2014 Nov 1;20(21):5384-91 PMID: 25204552
  27. Molecular and cellular insights into T cell exhaustion.
    Nat Rev Immunol. 2015 Aug;15(8):486-99 PMID: 26205583
  28. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
    N Engl J Med. 2015 Sep 24;373(13):1270-1 PMID: 26398076
  29. Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.
    Cancer Res. 2016 Mar 1;76(5):1031-43 PMID: 26676749
  30. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
    Ann Oncol. 2016 Apr;27(4):559-74 PMID: 26715621
  31. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
    J Clin Oncol. 2016 May 1;34(13):1510-7 PMID: 26951310
  32. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
    Nat Rev Cancer. 2016 May;16(5):275-87 PMID: 27079802
  33. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Lancet Oncol. 2016 Jul;17(7):956-965 PMID: 27247226
  34. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
    Immunity. 2016 Jun 21;44(6):1255-69 PMID: 27332730
  35. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    J Clin Oncol. 2016 Nov 10;34(32):3838-3845 PMID: 27646946
  36. Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.
    Oncotarget. 2016 Nov 15;7(46):75379-75393 PMID: 27683114
  37. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
    N Engl J Med. 2016 Nov 10;375(19):1856-1867 PMID: 27718784
  38. Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
    Genome Med. 2016 Oct 25;8(1):111 PMID: 27782862
  39. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
    Cancer. 2017 Apr 1;123(7):1259-1271 PMID: 27906454
  40. Resistance to PD1/PDL1 checkpoint inhibition.
    Cancer Treat Rev. 2017 Jan;52:71-81 PMID: 27951441
  41. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
    J Clin Oncol. 2017 May 10;35(14):1542-1549 PMID: 28328302
  42. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    BMC Med. 2017 Jun 2;15(1):110 PMID: 28571578
  43. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
    N Engl J Med. 2017 Oct 5;377(14):1345-1356 PMID: 28889792
  44. Tim-3, Lag-3, and TIGIT.
    Curr Top Microbiol Immunol. 2017;410:127-156 PMID: 28900677
  45. Quality-of-life outcomes in patients with advanced melanoma: A review of the literature.
    Pigment Cell Melanoma Res. 2017 Jan;30(6):511-520 PMID: 28950054
  46. Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity.
    JCI Insight. 2017 Dec 7;2(23): PMID: 29212947
Article Info
Journal
Journal of dental research
Abbr.
J Dent Res
ISSN
1544-0591
DOI
10.1177/0022034518759464
Published
2018-00-00
Epub
2018-00-28
Pages
622-626
Language
English
Region
United States
NLM ID
0354343
PMCID
PMC6728550
Subset
IM
Grants
NCI NIH HHS · P50 CA097190 · United States
NCI NIH HHS · T32 CA060397 · United States
External Links
PubMed source DOI: 10.1177/0022034518759464 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2